Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Endometrial cancer is the most common gynecologic malignancy in developed countries. The antibody–drug conjugate (ADC) sacituzumab govitecan (SG) targets trophoblast cell‐surface antigen‐2 (Trop‐2) – a cell‐surface glycoprotein highly expressed in many epithelial tumors – and delivers the active met...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Emanuele, Manara, Paola, Lopez, Salvatore, Bellone, Stefania, Bonazzoli, Elena, Manzano, Aranzazu, Zammataro, Luca, Bianchi, Anna, Zeybek, Burak, Buza, Natalia, Tymon‐Rosario, Joan, Altwerger, Gary, Han, Chanhee, Menderes, Gulden, Huang, Gloria S., Ratner, Elena, Silasi, Dan‐Arin, Azodi, Masoud, Hui, Pei, Schwartz, Peter E., Scambia, Giovanni, Santin, Alessandro D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053235/
https://www.ncbi.nlm.nih.gov/pubmed/31891442
http://dx.doi.org/10.1002/1878-0261.12627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053235/
https://www.ncbi.nlm.nih.gov/pubmed/31891442
http://dx.doi.org/10.1002/1878-0261.12627

Ejemplares similares